BlackRock Group Form 8.3 - Allergan PLC (2490J)
April 08 2020 - 10:20AM
UK Regulatory
TIDM0Y7T
RNS Number : 2490J
BlackRock Group
08 April 2020
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing BlackRock, Inc.
(Note 1)
Company dealt in Allergan plc
=========================
Class of relevant security US$0.0001 ordinary shares
to which the dealings
being disclosed relate
(Note 2)
=========================
Date of dealing 07 April 2020
=========================
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the
class of relevant
security dealt in (Note 3)
Long Short
Number (%) Number (%)
=========== ======= =========== ======
(1) Relevant securities 21,214,687 (6.44%) 47,186 (0.01%)
==================== ===================
(2) Derivatives (other
than options) 4,285,046 (1.30%) 39,224 (0.01%)
==================== ===================
(3) Options and agreements
to purchase/sell 0 (0.00%) 0 (0.00%)
==================== ===================
Total 25,499,733 (7.74%) 86,410 (0.02%)
==================== ===================
(b) Interests and short positions in relevant securities of the
company, other than the class dealt
in (Note 3)
Class of relevant security: Long Short
Number (%) Number (%)
========= ====== =========== ======
(1) Relevant securities
=================== =====================
(2) Derivatives (other
than options)
=================== =====================
(3) Options and agreements
to purchase/sell
=================== =====================
Total
=================== =====================
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit
(Note 5)
Purchase 4,793 USD 178.2600
====================================== ====================
Purchase 14 USD 179.4536
====================================== ====================
Purchase 691 USD 179.6727
====================================== ====================
Purchase 5,040 USD 179.7878
====================================== ====================
Purchase 66 USD 180.0700
====================================== ====================
Sale 5,757 USD 178.2600
====================================== ====================
Sale 1,987 USD 179.6978
====================================== ====================
Sale 455 USD 180.1172
====================================== ====================
Sale 989 USD 180.1173
====================================== ====================
Please note: there was also a Transfer In of 5,864 Shares
(b) Derivatives transactions (other than options transactions)
Product Nature of transaction Number of relevant Price per
name, (Note 6) securities unit
e.g. CFD (Note 7) (Note 5)
CFD Reducing Short 870 USD 179.6644
===================== ================== ============
CFD Reducing Short 3,200 USD 179.7666
===================== ================== ============
CFD Reducing Short 40 USD 180.2383
===================== ================== ============
CFD Reducing Short 4 USD 180.3600
===================== ================== ============
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product Writing, Number of Exercise Type, Expiry Option
name, selling, securities price e.g. American, date money paid/received
e.g. call purchasing, to which European per unit
option varying the option etc. (Note 5)
etc. relates (Note
7)
(ii) Exercising
Product name, Number of securities Exercise price
e.g. call option per unit (Note
5)
(d) Other dealings (including transactions in respect of new
securities) (Note 4)
Nature of transaction Details Price per unit
(Note 8) (if applicable)
(Note 5)
Return of Stock 100 N/A
on Loan
============== ====================
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and
any other person relating to the voting rights of any relevant
securities under any option referred to
on this form or relating to the voting rights or future
acquisition or disposal of any relevant securities to
which any derivative referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure 08 April 2020
Contact name Jana Blumenstein
================
Telephone number +44 20 7743 3650
================
If a connected EFM, name
of offeree/offeror with
which connected
================
If a connected EFM, state
nature of connection (Note
10)
================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ISEUPUAPCUPUGPR
(END) Dow Jones Newswires
April 08, 2020 10:20 ET (14:20 GMT)
Allergan (LSE:0Y7T)
Historical Stock Chart
From Apr 2024 to May 2024
Allergan (LSE:0Y7T)
Historical Stock Chart
From May 2023 to May 2024
